Talis Biomedical downgraded by BTIG Research
$TLIS
Biotechnology: Laboratory Analytical Instruments
Industrials
BTIG Research downgraded Talis Biomedical from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2022 | $3.00 | Neutral → Underperform | BofA Securities |
| 9/27/2021 | $10.00 → $7.00 | Neutral → Underweight | JP Morgan |
| 8/31/2021 | Buy → Neutral | BTIG Research | |
| 8/12/2021 | $9.00 | Overweight → Neutral | Piper Sandler |
| 8/11/2021 | $17.00 → $10.00 | Overweight → Neutral | JP Morgan |
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a
REDWOOD CITY, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended June 30, 2023, and provided a business update. Recent Business Highlights Initiated clinical study to support COVID-19 510(k) submission for clearance of the Talis One® systemPresented positive data at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) annual meeting differentiating the planned Talis One test menu Development-stage chlamy
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o
4 - Talis Biomedical Corp (0001584751) (Issuer)
4 - Talis Biomedical Corp (0001584751) (Issuer)
4 - Talis Biomedical Corp (0001584751) (Issuer)
REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions. As part of this process, the Company's Board of Directors has appointed a special committee of independent, disinterested directors to consider a
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section o
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical's w
15-12G - Talis Biomedical Corp (0001584751) (Filer)
25-NSE - Talis Biomedical Corp (0001584751) (Subject)
8-K - Talis Biomedical Corp (0001584751) (Filer)
SC 13D/A - Talis Biomedical Corp (0001584751) (Subject)
SC 13G/A - Talis Biomedical Corp (0001584751) (Subject)
SC 13G - Talis Biomedical Corp (0001584751) (Subject)
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (POC), today announced that it has appointed Dr. Andrew A. Lukowiak as president and chief scientific officer, effective August 1, 2023. Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies. As a member of the executive leadership team, he will be responsible for leading the assay development, platf
REDWOOD CITY, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced Heiner Dreismann has joined its board of directors, effective immediately. Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director. "Heiner's entrepreneurial vision and track record leading multiple corporate functions over the course of his 20-year tenure at Roche Diagnostics are ideal for the opportunities Talis Bio is
MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (NASDAQ:TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that Rob Kelley, the Company's current Chief Commercial Officer, has been promoted to Chief Executive Officer and Director, effective immediately. Brian Blaser has stepped down from the positions of President, Chief Executive Officer and Director, due to personal matters. About Rob KelleyMr. Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Company's Chief Co
BofA Securities downgraded Talis Biomedical from Neutral to Underperform and set a new price target of $3.00
JP Morgan downgraded Talis Biomedical from Neutral to Underweight and set a new price target of $7.00 from $10.00 previously
BTIG Research downgraded Talis Biomedical from Buy to Neutral
4 - Talis Biomedical Corp (0001584751) (Issuer)
4 - Talis Biomedical Corp (0001584751) (Issuer)
4 - Talis Biomedical Corp (0001584751) (Issuer)